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Rheumatoid arthritis (RA) is a chronic
inflammatory autoimmune disease. In the
majority of patients the course is progres-
sive and leads to destruction of joints,
functional disability, reduced quality of
life and increased morbidity and mortal-
ity. Advances in treatment for RA have
been associated with an improvement in
the health status of patients with RA in
recent years.1 While the management of
RA varies widely across Europe,2 the
underlying pathophysiology does not dif-
fer between countries. A cross-sectional
comparison of patients with RA in 15
different countries (largely European)
revealed great variation in the drug
management of patients with RA, includ-
ing the delay in starting a disease-modify-
ing antirheumatic drug (DMARD)
ranging from ,6 to .12 months, use of
methotrexate (,80% of patients in the
UK and Serbia had received methotrexate)
and use of biological agents (.40% in
France and Ireland vs. ,10% in Serbia and
Poland).3 It is also noteworthy that
disease activity scores varied and were
highest, on average, in Serbia and Poland.3
Although tumour necrosis factor (TNF)
inhibitors have undoubtedly significantly
advanced the treatment of RA, they are a
higher cost treatment option and may
not be suitable for all patients.4 Hence,
guidelines have been developed in order to
assist the appropriate use of TNF inhibi-
tors within individual countries.
In order to establish the level of access
to TNF inhibitors across Europe,
European guidelines were translated and
reviewed with regard to their similarities
and differences in the recommended
criteria for the initiation of TNF inhibi-
tion. Particular attention was paid to
recommended duration of disease and
prior treatment with DMARDs, as well
as disease activity levels.
The guidelines selected for inclusion were
those from Belgium,5 Czech Republic,6
Denmark,7 France,8 9 Germany,10 Italy,11
Romania,12 Spain,13 Sweden14 and the
UK.15 These were chosen to provide a fair
geographical spread of countries, including
countries with differing population densi-
ties and different levels of TNF inhibitor
usage. Table 1 provides an overview of the
recommendations made in these guidelines.
Duration of disease prior to initiation of
anti-TNF therapy
It is clear that the duration of disease prior
to the recommended initiation of TNF
inhibitors is highly variable. The general
consensus from national guidelines suggests
that TNF inhibition could be started
between 3 and 6 months following con-
firmed diagnosis of RA and failure of
treatment with, usually, two DMARDs
(including methotrexate). However, in the
UK and Czech Republic, at least a year
needs to elapse from RA diagnosis to TNF
inhibitor initiation unless the patient can-
not tolerate DMARDs, in which case it is
possible to start treatment after only a few
months.6 15 This is in dramatic contrast to
the Spanish guidelines, which suggest the
theoretical possibility (although highly
unlikely) of initiating TNF inhibition prior
to a confirmed diagnosis of RA, if there is a
high probability of RA in initial stages with
especially aggressive progression sus-
pected.13 While the British Society for
Rheumatology (BSR) guidance acknowl-
edges the existence of evidence for the
benefit of TNF inhibitors in patients with
early RA and patients that are DMARD
naı¨ve, it does not recommend this
approach.15 A recent editorial regarding the
need to update the BSR guidelines suggests
that the reasons are financial and acknowl-
edges that the UK BSR guidelines are out of
kilter with other national guidelines.16
There is a growing body of evidence to
suggest that treatment with disease mod-
ifying agents should be initiated early in
the course of the disease. Importantly,
Nell et al investigated the effects of delays
to the initiation of DMARD therapy on
long-term outcomes for patients with
RA.17 By comparing two groups of
patients, one with a median symptom
duration of 3 months and another with a
median symptom duration of 12 months,
they established that very early therapy
provided significant improvements in dis-
ease activity, joint destruction and func-
tional outcome. Furthermore, these
differences were most apparent within
the first 3 months of treatment, suggesting
a ‘‘window of opportunity’’ in very early
disease to rapidly halt disease progression.18
The Spanish guidelines cite such evidence
to justify their stance of initiating DMARD
therapy as soon as, or possibly before, the
diagnosis of RA is confirmed.13 17–20
Evidence also exists for the efficacy of
all the currently available TNF inhibitors
early in the course of RA.21 The Early
Rheumatoid Arthritis (ERA) trial showed
that etanercept monotherapy was super-
ior to methotrexate in reducing subse-
quent radiographic erosions over 2 years
in patients with early erosive RA; at
24 months the American College of
Rheumatology 20% (ACR20) response in
the etanercept group was significantly
higher than that for the methotrexate
group (72% vs 59%, respectively,
p = 0.005)22 A subanalysis of patients with
early RA in the Anti-TNF Therapy in RA
with Concomitant Therapy (ATTRACT)
study showed that early initiation of
infliximab in combination with metho-
trexate provided significant reductions in
radiological progression over 2 years com-
pared with methotrexate alone.23 Finally,
the PREMIER study demonstrated that
combination adalimumab plus metho-
trexate was more effective than either
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agent as monotherapy in patients with
early, aggressive RA.24
By comparing therapeutic strategies in
patients newly diagnosed with RA, the
BeSt study showed that initial combina-
tion therapy with methotrexate plus a TNF
inhibitor provided earlier functional
improvement and less progression of radio-
graphic joint damage than either sequential
monotherapy or step-up combination ther-
apy (conventional DMARDs).25 There is
also evidence, from the Trial of Etanercept
and Methotrexate with Radiographic
Patient Outcomes (TEMPO) study, that
in patients who initially receive and fail
DMARDs other than methotrexate, com-
bination etanercept and methotrexate is
more effective than either agent alone.26
Furthermore, no increase in toxicity was
associated with combination treatment
with etanercept plus methotrexate.26
Disease activity
Across Europe the goals of RA treatment
with TNF inhibitors vary considerably.
While a reduction in disease activity is a
common theme, the levels of activity
designated for initiation and/or cessation
of TNF inhibitors differ.
When specified, a Disease Activity
Score using 28 joint counts (DAS28) of
over 5.1 is commonly used to define
highly active disease that could qualify
for TNF inhibition. The BSR guidelines
for the prescribing of TNF inhibitors in
the UK require two DAS measurements at
least 1 month apart to confirm the
ongoing activity of disease.15 In Romania
the patient must also have five or more
joints with active synovitis (tender and
swollen joints) plus two of the following
three criteria: morning stiffness for over
60 min; erythrocyte sedimentation rate
(ESR) .28 mm/h; C-reactive protein
(CRP) .20 mg/litre (quantitative determi-
nation).12 However, in Spain and Sweden
moderate disease activity also qualifies for
the consideration of TNF inhibitors,
defined as DAS28 .3.2.13 14 In Spain,
patients who in spite of achieving remis-
sion or low DAS28 show radiographic
progression or persistent inflammation in
joints of special functional value, may also
be considered for TNF inhibitors.13
In order for treatment with TNF
inhibitors to continue unaltered, guide-
lines generally require a European League
Against Rheumatism (EULAR) response
to be demonstrated. EULAR response is
defined as DAS28 ,3.2 or DAS28 ,5.1
and a decrease in DAS28 by at least 1.2
points. Denmark requires that a satisfac-
tory response is achieved, although it is
not clearly specified what this implies.7 In
Spain, in keeping with their aggressive
treatment strategy, treatment should be
altered if a of DAS28 ,3.2 is not achieved,
however, if even this is not possible, a
maximum of 5 swollen and painful joints
among 66 and 68 joints, respectively,
should be the aim of treatment.13
CONCLUSIONS
It is clear that there is obvious variability in
the framework for initiation of TNF
inhibitors across Europe. The clinical evi-
dence base available to the national rheu-
matological societies concerned is largely
the same, although obviously expanding as
time progresses. Therefore it is interesting
that despite many similarities, there are
differences in the criteria for initiation.
It is also apparent that a number of
areas are not covered by the guidelines.
For example, initial DMARD therapy is a
requirement of all the European guide-
lines, and all state inadequate response as
a criterion for changing to anti-TNF
therapy. However, guidelines do not
provide a clear definition of inadequate
response to DMARDs. Such definitions
are essential to ensure treatment pro-
gresses in a way that provides optimal
outcomes for the patient.
Even with the similarities between
guidelines, such as they are, TNF inhibitor
prescribing patterns vary greatly between
countries; it would seem that the pro-
spects for people diagnosed with RA are
substantially influenced by geographical
location, possibly due to the different
methods of funding healthcare provision.
Other factors may give rise to such
differences in treatment, such as levels of
recognition of guidelines, the presence or
absence of specialised rheumatological
clinics, including early RA clinics, and
familiarity with TNF inhibitors.
It should be possible for patients to be
certain that they are receiving the best
advice regarding their treatment, based on
clinical evidence and experience, rather
than the financial situation, or other
influencing factors, in their respective
healthcare organisation. In order to achieve
this we propose that European guidance,
based upon a thorough evidence review,
should be prepared and made universally
available in order to promote more con-
sistent access to effective therapy.
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